SEC Form 4 · accession 0000950138-17-000518
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew K Harbaugh
Officer — Exec. VP & CFO
Period of report
Jul 1, 2017
Accepted (ET)
Jul 5, 2017 · 4:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Jul 1, 2017 | F | 1,620 | $44.81 | D | 74,668 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes 203 shares acquired on March 31, 2017 under the Mallinckrodt employee stock purchase plan.